Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$76.41
+0.7%
$67.71
$60.47
$76.80
$236.90B0.56.29 million shs4.44 million shs
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$44.21
+0.6%
$50.81
$43.73
$69.10
$89.62B0.3915.96 million shs13.24 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$776.75
-0.6%
$761.41
$399.26
$800.78
$738.04B0.343.07 million shs2.76 million shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
+0.53%+7.10%+12.00%+13.87%+3.24%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-1.55%-10.29%-18.94%-10.05%-35.73%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+6.00%+4.82%+0.46%+21.15%+92.59%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AstraZeneca PLC stock logo
AZN
AstraZeneca
1.6439 of 5 stars
1.33.01.70.01.90.03.1
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
4.9397 of 5 stars
4.14.02.54.02.81.71.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.688 of 5 stars
2.43.02.54.02.61.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.57
Moderate Buy$81.006.01% Upside
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.11
Hold$60.0035.72% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$757.95-2.42% Downside

Current Analyst Ratings

Latest AZN, LLY, and BMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$900.00 ➝ $1,001.00
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$850.00 ➝ $900.00
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$850.00 ➝ $892.00
4/30/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00 ➝ $885.00
4/26/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$80.00 ➝ $82.00
4/26/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Perform ➝ Market Perform$55.00 ➝ $48.00
4/26/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $43.00
4/18/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $52.00
4/16/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Hold
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$650.00 ➝ $723.00
(Data available from 5/1/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AstraZeneca PLC stock logo
AZN
AstraZeneca
$45.81B5.17$5.46 per share13.99$12.10 per share6.31
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$45.01B1.99$12.35 per share3.58$8.16 per share5.42
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B21.63$8.04 per share96.66$11.44 per share67.90

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AstraZeneca PLC stock logo
AZN
AstraZeneca
$5.96B$2.0437.4616.401.3713.30%30.42%11.62%7/26/2024 (Estimated)
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$8.03B-$3.10N/A6.3215.39-13.50%8.83%2.50%7/25/2024 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$5.80133.9241.991.6115.36%51.22%9.94%8/13/2024 (Estimated)

Latest AZN, LLY, and BMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2024Q1 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.53$2.58+$0.05$2.68$8.94 billion$8.77 billion      
4/25/2024Q1 24
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-$4.53-$4.40+$0.13$9.69$11.45 billion$11.87 billion      
2/8/202412/31/2023
AstraZeneca PLC stock logo
AZN
AstraZeneca
$0.74$0.73-$0.01$1.15$12.07 billion$12.02 billion    
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    
2/2/202412/31/2023
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.55$1.70+$0.15$2.53$11.19 billion$11.48 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.932.53%+1.18%94.61%1 Years
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.405.43%+8.20%N/A N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.67%+15.15%89.66%10 Years

Latest AZN, LLY, and BMY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/1/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
quarterly$0.604.72%4/4/20244/5/20245/1/2024
2/8/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
Semi-Annual$0.96502.3%2/22/20242/23/20243/25/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.73
0.89
0.70
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.99
1.11
0.99
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.69
0.94
0.73

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
76.41%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
0.09%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
89,9003.10 billionN/AOptionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
34,1002.03 billion2.03 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.16 million948.93 millionOptionable

AZN, LLY, and BMY Headlines

SourceHeadline
Searle & CO. Has $3.69 Million Stake in Eli Lilly and Company (NYSE:LLY)Searle & CO. Has $3.69 Million Stake in Eli Lilly and Company (NYSE:LLY)
marketbeat.com - May 1 at 5:02 PM
Q1 Earnings Seasons Picks & Pans: The 4 Biggest Stock Winners (and 3 Losers)Q1 Earnings Seasons Picks & Pans: The 4 Biggest Stock Winners (and 3 Losers)
investorplace.com - May 1 at 3:36 PM
Eli Lilly Shoots Higher: Its Time To Be CautiousEli Lilly Shoots Higher: It's Time To Be Cautious
seekingalpha.com - May 1 at 2:41 PM
Eli Lilly and Company (NYSE:LLY) Trading Down 0.7%Eli Lilly and Company (NYSE:LLY) Trading Down 0.7%
marketbeat.com - May 1 at 1:59 PM
Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,001.00 at BMO Capital MarketsEli Lilly and Company (NYSE:LLY) Price Target Raised to $1,001.00 at BMO Capital Markets
marketbeat.com - May 1 at 1:34 PM
Eli Lilly: The GLP-1 Wonder Continues, A Bullish Beat And RaiseEli Lilly: The GLP-1 Wonder Continues, A Bullish Beat And Raise
seekingalpha.com - May 1 at 1:09 PM
Eli Lilly: Management Raises 2024 Guidance, Driven By GLP-1 FranchiseEli Lilly: Management Raises 2024 Guidance, Driven By GLP-1 Franchise
seekingalpha.com - May 1 at 12:44 PM
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts OutlookETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
zacks.com - May 1 at 12:01 PM
Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices PlungeStock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge
investorplace.com - May 1 at 11:59 AM
Eli Lilly: Bloated StockEli Lilly: Bloated Stock
seekingalpha.com - May 1 at 11:07 AM
Eli Lilly and Company (NYSE:LLY) Issues  Earnings ResultsEli Lilly and Company (NYSE:LLY) Issues Earnings Results
marketbeat.com - May 1 at 10:58 AM
Nearly 50% of Billionaire Stanley Druckenmillers Portfolio Is Invested in These 4 StocksNearly 50% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 4 Stocks
fool.com - May 1 at 10:00 AM
Eli Lilly reports 67% increase in Q1 2024 net incomeEli Lilly reports 67% increase in Q1 2024 net income
pharmaceutical-technology.com - May 1 at 9:15 AM
Eli Lilly and Company (NYSE:LLY) Receives Overweight Rating from Cantor FitzgeraldEli Lilly and Company (NYSE:LLY) Receives Overweight Rating from Cantor Fitzgerald
americanbankingnews.com - May 1 at 5:36 AM
This Options-Backed Strategy Can Help You Dodge the Stock Market’s HazardsThis Options-Backed Strategy Can Help You Dodge the Stock Market’s Hazards
finance.yahoo.com - May 1 at 4:15 AM
Eli Lilly and Co (LLY) Q1 2024 Earnings Call Transcript Highlights: Stellar Growth and ...Eli Lilly and Co (LLY) Q1 2024 Earnings Call Transcript Highlights: Stellar Growth and ...
finance.yahoo.com - May 1 at 4:15 AM
Q1 2024 Eli Lilly and Co Earnings CallQ1 2024 Eli Lilly and Co Earnings Call
finance.yahoo.com - May 1 at 4:15 AM
Contrasting Eli Lilly and Company (NYSE:LLY) & Sanofi (OTCMKTS:SNYNF)Contrasting Eli Lilly and Company (NYSE:LLY) & Sanofi (OTCMKTS:SNYNF)
americanbankingnews.com - May 1 at 1:20 AM
Raymond James Financial Services Advisors Inc. Boosts Holdings in Eli Lilly and Company (NYSE:LLY)Raymond James Financial Services Advisors Inc. Boosts Holdings in Eli Lilly and Company (NYSE:LLY)
marketbeat.com - May 1 at 12:51 AM
These 3 Companies Recently Lifted GuidanceThese 3 Companies Recently Lifted Guidance
zacks.com - April 30 at 6:56 PM
Eli Lilly, 3M rise; MicroStrategy, Chegg fall, Tuesday, 4/30/2024Eli Lilly, 3M rise; MicroStrategy, Chegg fall, Tuesday, 4/30/2024
msn.com - April 30 at 6:14 PM
Eli Lilly and Company (NYSE:LLY) Shares Up 6%Eli Lilly and Company (NYSE:LLY) Shares Up 6%
marketbeat.com - April 30 at 3:37 PM
Cantor Fitzgerald Reiterates "Overweight" Rating for Eli Lilly and Company (NYSE:LLY)Cantor Fitzgerald Reiterates "Overweight" Rating for Eli Lilly and Company (NYSE:LLY)
marketbeat.com - April 30 at 2:43 PM
Eli Lilly and Co (LLY) Surpasses Q1 Earnings Estimates and Raises Full-Year GuidanceEli Lilly and Co (LLY) Surpasses Q1 Earnings Estimates and Raises Full-Year Guidance
finance.yahoo.com - April 30 at 1:14 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AstraZeneca logo

AstraZeneca

NASDAQ:AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Bristol-Myers Squibb logo

Bristol-Myers Squibb

NYSE:BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.